Cerluten
Cerluten is a complex peptide bioregulator preparation derived from brain tissue, developed at the St. Petersburg Institute of Bioregulation and Gerontology for research in cognitive aging, neurodegeneration, and cerebral function. Distinguished from cortagen (AEDP), which is a single tetrapeptide CNS bioregulator.
Cerluten is a complex peptide preparation obtained from young animal brain tissue through acid extraction and purification. It contains a mixture of short regulatory peptides that selectively target neurons and glial cells in the central nervous system.
Overview
Cerluten is the complex peptide preparation counterpart to cortagen in Khavinson's bioregulator program for the central nervous system. While cortagen is a single tetrapeptide (AEDP) with defined molecular properties and demonstrated effects on neural gene expression, cerluten contains the full complement of regulatory peptides extractable from brain tissue. This distinction parallels other organ systems in the Cytomed line where both a defined tetrapeptide and a complex preparation exist (e.g., ovagen and svetinorm for liver).
The primary research applications of cerluten center on age-related cognitive decline, neurodegenerative conditions, and restoration of cerebral function following ischemic or traumatic injury. The preparation has been used clinically in Russia as a dietary supplement for cognitive support in elderly populations.
Mechanism of Action
Cerluten is proposed to act through tissue-specific peptide-DNA interactions in neural cells, modulating gene expression patterns associated with neuronal survival, synaptic plasticity, and glial support functions. As a complex preparation, cerluten likely engages multiple regulatory targets in CNS tissue simultaneously.
Proposed mechanisms include:
- Modulation of neurotrophic factor expression, including BDNF and NGF, in neurons and supporting cells
- Regulation of genes involved in synaptic plasticity and long-term potentiation
- Influence on anti-apoptotic pathways (Bcl-2 family) in neurons exposed to ischemic or oxidative stress
- Normalization of inflammatory signaling in microglia and astrocytes
- Support of myelination through effects on oligodendrocyte gene expression
Research on cortagen (AEDP) has demonstrated that CNS-targeting peptides can modulate expression of genes involved in neurogenesis and neuroprotection, including effects on chromatin remodeling in neural tissue. Cerluten, as a more complex preparation, may engage additional regulatory pathways beyond those accessible to a single tetrapeptide.
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Neurodegenerative Disease Research
Preliminary research has explored cerluten's potential in neurodegenerative conditions. In cell culture models relevant to Alzheimer's disease, brain-derived peptides demonstrated protective effects against amyloid-beta toxicity, reducing neuronal death and oxidative damage markers. However, these findings remain at the preclinical stage and have not been validated in clinical trials.
Neuroprotection in Ischemic Models
Research in experimental cerebral ischemia models examined whether brain-derived peptide preparations could reduce neuronal damage. In animal models of focal ischemia, treatment with CNS peptide bioregulators was associated with reduced infarct volume, decreased neuronal apoptosis in the penumbral zone, and improved functional recovery. These effects were attributed to upregulation of anti-apoptotic gene expression and enhanced neurotrophic signaling.
Comparison with Cortagen
While both cerluten and cortagen target CNS tissue, they represent different approaches within the bioregulator framework. Cortagen (AEDP) is a defined molecule suitable for mechanistic studies and reproducible dosing. Cerluten, as a complex preparation, may provide broader biological coverage but with less molecular precision. Studies comparing the two directly are limited, though both have shown neural gene expression modulation in their respective research contexts.
Cognitive Aging
The primary research focus for cerluten has been age-related cognitive decline. Studies in aged animal models demonstrated improvements in learning and memory tasks following administration of brain-derived peptide preparations. Khavinson's group reported that elderly subjects receiving combinations of brain and pineal peptide bioregulators showed improvements in cognitive function tests, with effects persisting beyond the treatment period (Khavinson & Morozov, 2003).
In a notable long-term study, Khavinson et al. administered peptide bioregulators including cerluten and epithalon to elderly subjects over several years. The treatment group showed reduced mortality and improved cognitive and physical function parameters compared to controls (Khavinson et al., 2003).
Safety Profile
Cerluten has been available as a dietary supplement in Russia for over a decade with no significant adverse effects reported in available literature. As a preparation of naturally derived short peptides administered orally, systemic CNS penetration and potency are expected to be modest. The preparation is generally well tolerated based on reported clinical use in elderly populations. No formal safety trials meeting international regulatory standards have been published. Individuals with active neurological disease, seizure disorders, or those receiving psychoactive medications should consult medical professionals before use.
Pharmacokinetic Profile
- Half-life
- Not established
Quick Start
- Route
- Oral (capsules)
Molecular Structure
- Formula
- Not applicable (multi-peptide preparation)
- CAS
- Not available
Research Protocols
oral
As a preparation of naturally derived short peptides administered orally, systemic CNS penetration and potency are expected to be modest.
Interactions
Peptide Interactions
While both cerluten and cortagen target CNS tissue, they represent different approaches within the bioregulator framework. Cortagen (AEDP) is a defined molecule suitable for mechanistic studies and reproducible dosing. Cerluten, as a complex preparation, may provide broader biological coverage bu...
Quality Indicators
What to look for
- Well-established safety profile
Frequently Asked Questions
References (6)
- [3]Khavinson VKh (2002). Peptides and ageing. Neuro Endocrinol Lett (2002)
- [5]Ilina A et al. (2020). Neuroprotective properties of short peptides based on the structure of [BDNF](/docs/peptides/bdnf). Bull Exp Biol Med (2020)
- [6]Ilina A et al Neuroprotective properties of short peptides based on the structure of BDNF. Bull Exp Biol Med (2020)
- [2][Khavinson VKh & Malinin VV (2005). Gerontological aspects of genome peptide regulation. Karger (2005)
- [4][Ashapkin V et al. (2020). Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Mol Biol Rep (2020)
- [1][Khavinson VKh & Morozov VG (2003). Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett (2003)
Cerebrolysin
Cerebrolysin is a neuropeptide preparation derived from porcine brain proteins containing neurotrophic factors that mimic BDNF and NGF, extensively researched for Alzheimer's disease, stroke recovery, traumatic brain injury, and cognitive enhancement.
Cholecystokinin (CCK)
Cholecystokinin (CCK) is a gut-brain peptide existing in multiple bioactive forms (CCK-8, CCK-33, CCK-58) that signals through CCK-A (peripheral) and CCK-B (CNS) receptors. It mediates gallbladder contraction, pancreatic secretion, satiety, and anxiety/panic responses, with CCK-4 serving as a validated panic-induction model.